Cytochrome P450 enzymes are increasingly investigated due to their potential application as biocatalysts with high regio-and/or stereo-selectivity and under mild conditions. Vitamin D 3 (VD 3 ) metabolites are of pharmaceutical importance and are applied for the treatment of VD 3 deficiency and other disorders. However, the chemical synthesis of VD 3 derivatives shows low specificity and low yields. In this study, cytochrome P450 CYP109A2 from Bacillus megaterium DSM319 was expressed, purified, and shown to oxidize VD 3 with high regio-selectivity. The in vitro conversion, using cytochrome P450 reductase (BmCPR) and ferredoxin (Fdx2) from the same strain, showed typical Michaelis-Menten reaction kinetics. A whole-cell system in B. megaterium overexpressing CYP109A2 reached 76 AE 5% conversion after 24 h and allowed to identify the main product by NMR analysis as 25-hydroxylated VD 3 . Product yield amounted to 54.9 mgÁL À1 Áday À1 , rendering the established whole-cell system as a highly promising biocatalytic route for the production of this valuable metabolite. The crystal structure of substrate-free CYP109A2 was determined at 2.7
Introduction
Vitamin D 3 (VD 3 ) is a secosteroid that is produced in the human skin from the precursor compound 7-dehydrocholesterol upon exposure to UV light irradiation, resulting in the opening of the precursor B-ring. Afterward, VD 3 is metabolized successively in the liver and kidneys to form two derivatives that are highly important for human health, the 25-hydroxyvitamin D 3 [25(OH)VD 3 ] and 1a,25-dihydroxyvitamin D 3 [1a,25(OH) 2 VD 3 , Fig. 1 ]. While the latter derivative is the biologically active form of VD 3 , the former one is the most abundant circulating metabolite of VD 3 in the blood and is, therefore, considered to be an optimal indicator of the nutritional status concerning VD 3 in patients [1, 2] . Maintaining an optimal level of 25(OH)VD 3 is crucial for reducing the risk of several chronic diseases or cancer conditions [3] . Moreover, the 25(OH)VD 3 metabolite is acknowledged for better absorption properties as compared with VD 3 in certain supplement-based treatments [4, 5] . Unfortunately, chemical synthesis of VD 3 derivatives is a challenging, multistep procedure resulting in low product yields, limiting their usefulness as therapeutic dietary supplements [6] . Biotechnological approaches involving enzymes capable of specifically oxidizing VD 3 offer an attractive alternative to circumvent such limitations.
In humans, the two consecutive VD 3 hydroxylation steps, at carbons C-25 and C-1, are catalyzed by proteins belonging to the cytochrome P450 superfamily (P450s or CYPs) [7] . The P450s are heme-containing enzymes that catalyze the monooxygenation of a large variety of organic substrates like steroids, fatty acids, and are generally known to be involved in the oxidative metabolism of xenobiotics and drugs. Considering the broad range of P450 substrates, the enzymes are of benefit to synthesis of pharmaceutically and biotechnologically valuable compounds, in particular when high regio-and stereo-selectivity of hydroxylation is required. Microbial P450s are favored, as they are soluble and more stable than their eukaryotic counterparts [8] [9] [10] . Thus far, only a few bacterial P450 enzymes have been reported that hydroxylate VD 3 to produce the desired 25(OH)VD 3 metabolite, like CYP105A1 from Streptomyces griseolus [11] or CYP107BR1 (Vdh) from Pseudonocardia autotrophica [12] . Most recently, our investigations led to the identification and characterization of another bacterial VD 3 -hydroxylase, cytochrome P450 CYP109E1 from Bacillus megaterium DSM319 [13] . The improvement of activity and/or regio-selectivity of the three abovementioned enzymes by protein engineering was supported by the knowledge of their structure-function relationships, due to determination of their crystal structures in both the open, substrate-free and closed, substrate-bound states [14] [15] [16] [17] [18] .
Here, we describe the identification and analysis of a new cytochrome P450 enzyme from B. megaterium DSM319, classified as CYP109A2, which shares 45% amino acid sequence identity with CYP109E1. Similar to CYP109E1, CYP109A2 exhibits 25-hydroxylation activity toward VD 3 , however, with significantly higher regio-selectivity. A whole-cell B. megaterium-based VD 3 oxidation system was established for CYP109A2 and resulted in higher yields of 25(OH)VD 3 as compared with the previously reported most productive variant of CYP109E1, i.e., mutant I85A [13] . The three-dimensional structure of CYP109A2 was obtained by X-ray crystallography and compared with the structures of other bacterial P450s that convert VD 3 , suggesting putative structural features associated with differences in substrate specificity and regio-selectivity. Fig. 1 . The activation pathway of VD 3 in mammals. First, VD 3 undergoes a C-25 hydroxylation resulting in the formation of 25(OH)VD 3 (in the liver) followed by the second hydroxylation at C-1 atom producing 1a,25(OH) 2 VD 3 (in the kidneys).
Results and Discussion
Identification, sequence analysis, and initial characterization of CYP109A2 Bioinformatic mining of the B. megaterium DSM319 genome previously led to identification of four genes putatively encoding for cytochrome P450 enzymes (CYP102A1, CYP106A1, CYP109E1, and CYP109A2) [18, 19] . Here, we focus on CYP109A2, the remaining P450 that has not been studied in detail yet. Its openreading frame (KEGG: BMD_2035) encodes for a 403 amino acid long protein containing three characteristic sequence motifs, which support its annotation as a P450 enzyme: (a) heme-binding domain signature proceeding the L helix (FxxGx(H/R)xCxG), (b) the acid-alcohol pair in the I helix (Glu244, Thr245), and (c) ExxR motif in the K helix (Fig. 2) . Interestingly, CYP109A2 shares 45% sequence identity with CYP109E1 from the same organism (the sequence identity with CYP106A1 and CYP102A1 is 36% and 24%, respectively). Comparative sequence analysis including proteins from different bacterial sources further shows that CYP109A2 shows significant sequence homology to VD 3 hydroxylating P450s from the CYP107 and CYP105 family [37% identity to CYP107BR1 (Vdh) from P. autotrophica, 36% to CYP107CB2 from Bacillus lehensis G1, 32% identity to CYP105A1 from S. griseolus, and 30% to CYP105A2 from P. autotrophica]. Residues in CYP109A2 with the highest degree of conservation have a role in heme binding or belong to substrate recognition site 4 (SRS4) (central part of I helix), whose residues have common roles in P450s associated with substrate binding, oxygen activation, and proton delivery during catalysis [20] . Other regions associated with substrate binding (SRS2, SRS5, and SRS6) are less well conserved, although relatively higher conservation levels may be observed in SRS5 or SRS6 upon pairwise comparison of P450s belonging to the same CYP family, such as CYP109A2 and CYP109E1. The lowest degree of conservation is displayed by the amino acids belonging to SRS1 (the BC loop region) and SRS3 (the G helix) (Fig. 2) .
Since a significant sequence similarity between bacterial P450s belonging to the same CYP family may correlate to similarities in substrate scope [21] , we set out to establish whether VD 3 , being a substrate for CYP109E1, is also converted by CYP109A2. To produce sufficient amounts of pure and functional CYP109A2 enzyme for the intended functional analysis, the cyp109a2 gene was cloned into the pET17b vector and expressed in Escherichia coli C43 (DE3) cells with high yield (4210 nmolÁL À1 ). The protein was purified by affinity chromatography and displayed characteristic P450 spectroscopic behavior, considering both the UV-visible spectrum of its oxidized ligand-free and reduced CO-bound forms (Fig. 3) . Spectroscopic analysis, thus, confirmed that the purified protein contained the correctly incorporated heme group and may be functional as a P450 enzyme.
CYP109A2 catalyzes regio-selective oxidation of vitamin D 3 in vitro Cytochromes P450 are external monooxygenases and thus require electrons for their catalytic activity from different (autologous or heterologous) redox partners [22] . Selection of suitable redox partners to support CYP109A2 activity was based on previous observations that B. megaterium cytochrome P450 reductase (BmCPR) and a ferredoxin (Fdx2) were able to support CYP106A1 with much higher efficiency than the commonly used AdR-Adx 4-108 (adrenodoxin reductaseadrenodoxin) redox partners [23] . Indeed, reconstitution of CYP109A2 activity was accomplished using both redox partner systems, but the CYP109A2-catalyzed in vitro reactions (200 lM, 1 h) yielded a significantly higher VD 3 conversion ratio when using the BmCPRFdx2 redox pair (36 AE 4%) (Fig. 4A) (Fig. 5 ).
These results demonstrate that the CYP109A2 in vitro activity toward VD 3 is lower than that of other previously characterized bacterial VD 3 hydroxylases [24] . In addition, CYP109A2 displays a lower substrate conversion ratio in comparison to its most closely related homolog CYP109E1, which was shown to convert 90% of VD 3 under the same conditions (when supported by the AdR-Adx 4-108 pair) [13] . The affinity for VD 3 is also lower in CYP109A2 as compared with wildtype CYP105A1 or Vdh, which showed K M values of 0.54 AE 0.09 lM and 13.5 AE 3.7 lM, respectively [12, 25] .
However, the regio-selectivity of CYP109A2, as evident from its product pattern of VD 3 conversion, is superior to that of the other bacterial VD 3 hydroxylases. CYP109A2 converts VD 3 into two products only, whereas previously it was shown that CYP109E1 converts the same substrate to seven products [13] . CYP105A1 and Vdh convert VD 3 to three products [12, 25] , while for the VD 3 25-hydroxylase CYP105A2 from P. autotrophica, the exact product profile is not yet determined [24] . Interestingly, upon comparison of the CYP109A2 product retention times with the available authentic standards and HPLC data previously obtained for CYP109E1, it was hypothesized and later shown (see below) that product P1 is 25-hydroxyvitamin D 3 . Therefore, to the best of our knowledge, the newly identified enzyme, CYP109A2 from B. megaterium, is the most regio-selective bacterial VD 3 hydroxylase characterized so far.
Whole-cell-based bioconversion of vitamin D 3 by CYP109A2
Our recent study of CYP109E1 has demonstrated that the B. megaterium-based whole-cell system may be an efficient and sustainable route to large-scale production of VD 3 metabolites like 25(OH)VD 3 [13] . B. megaterium is a Gram-positive, nonpathogenic bacterium and a well-studied biotechnologically applicable production host. Its use in the pharmaceutical and food industries is preferred due to the ability of this bacterium to grow on a variety of carbon sources and simple media as well as due to its high protein production capacity and plasmid stability [26, 27] . Importantly, as shown by research results considering various P450 enzymes, the B. megaterium offers certain advantages, of being not only a source of new, uncharacterized P450s but also a very good host for P450s and/or their homologous or heterologous redox partners [19, [28] [29] [30] . Use of the whole-cell expressed P450 (s) in a biotransformation process allows for regeneration of the expensive NADPH cofactor that is necessary for P450 activity.
The B. megaterium MS941 cells were transformed with expression plasmid pSMF2.1.CYP109A2, and using such a system 76 AE 5% of 200 lM VD 3 was successfully converted within 24 h into one main product P1 (90%) and one minor product P2 (10%) (Fig. 4B) . In comparison to the profile observed in vitro, the product ratio obtained in vivo is slightly changed, favoring generation of the main product P1 over product P2. The changes in the product profile are most probably caused by the fact that no heterologous redox partners were expressed along with CYP109A2, leaving only the endogenous B. megaterium redox proteins (which remain to be identified) to support its activity. In fact, it was recently observed that varying the redox partners for reconstitution of P450-based reactions can influence the observed product ratios [31, 32] .
Product isolation and identification by NMR analysis
As for the in vitro conversion of VD 3 by CYP109A2, the main hydroxylated product obtained by the in vivo conversion showed an identical retention time in HPLC analysis as the authentic standard of 25-hydroxyvitamin D 3 . To allow full characterization of the product(s) by NMR spectroscopy, the in vivo reactions were up-scaled to 400 mL of total culture volume (200 lM VD 3 ), and thus 16 mg of the product of interest (P1) was obtained. Unfortunately, the yields of product P2 were not sufficient to allow for the direct product identification by NMR. For the isolated product P1, the 1 H NMR and 13 C NMR spectra were recorded. It was observed that in comparison to standard VD 3 , product P1 showed resonances for an additional tertiary hydroxyl group (at C-25) in the (Fig. 6) . The NMR data are in accordance with reported literature (Table S1 ) [33, 34] .
Efficient biocatalytic production of 25-hydroxyvitamin D 3 by CYP109A2
Based on the results of the in vivo conversion of VD 3 performed by the CYP109A2-based whole-cell system, the yield of 25(OH)VD 3 was calculated to be 54.9 mgÁL À1 Áday
À1
. Hence, it becomes apparent that the production yield of the CYP109A2-based wholecell system is significantly higher as compared with other bacterial in vivo CYP-based systems known to produce the same product. For example, the previously studied CYP109E1 expressed in B. megaterium under the same conditions and reaction time produced 24.5 mgÁL À1 Áday À1 of 25(OH)VD 3 , whereas with its best mutant I85A, the achieved yield was 45 mgÁL À1 Áday À1 [13] . The yield achieved with the CYP109A2-based system is also higher than the yield reported for the most productive mutant of CYP105A1 (R73A/R84A), which produced 7.8 mg 25(OH) VD 3 ÁL À1 Áday À1 [14] . Only Vdh expressed in Amycolata autotrophica (now referred to as P. autotrophica) was reported to give a higher yield than CYP109A2 being 137 mgÁL À1 [35] . However, this value was obtained after 72 h, whereas in case of CYP109A2 described here, 54.9 mgÁL À1 was obtained already after 24 h.
Thus, the B. megaterium CYP109A2-based whole-cell system offers a very promising biotechnological alternative to the production of 25-hydroxyvitamin D 3 in comparison to other characterized P450 biocatalysts.
Crystal structure of substrate-free CYP109A2
In order to determine the geometry of its active site pocket and predict the residues responsible for VD 3 binding, the CYP109A2 enzyme was studied by X-ray crystallography. For crystallization, a C-terminally His-tagged protein was purified using the previously described three-step purification procedure, resulting in protein sample of > 98% purity and low polydispersity (12.2%) as confirmed by SDS/PAGE analysis and dynamic light scattering (DLS) measurements (data not shown). The substrate-free CYP109A2 crystallized in an orthorhombic space group (P2 1 2 1 2 1 ), with four monomers in the asymmetric unit and a solvent content of 50%. The crystal structure was solved at 2.7 A resolution by the molecular replacement method, using the previously determined structure of CYP109E1 (sequence similarity 45%, Protein Data Bank [PDB] entry 5L90, [18] ) as a search model (see Table 1 for data collection and refinement statistics). All four CYP109A2 molecules have well-defined electron density, except for the 15 or 16 N-terminal residues and the C-terminal His 6 -tags, for which no electron density was observed. The central parts of the BC loop, FG loop, and N-terminal end of the G helix show relatively high B-factors, related to high mobility of those regions, as generally observed in P450 crystal structures. The four CYP109A2 molecules found in the asymmetric unit have almost identical conformations [the root mean square deviation (r.m.s.d) of Ca-backbone atoms ranges between 0.36 and 0. 43 A]. Therefore, only one of the protein molecules will be described further. The structure of CYP109A2 (residues 16-401) exhibits the typical organization of a P450 domain, containing 15 helices (labeled A-L, A 0 , B 0 , and K 0 ) and 10 b-strands (arranged in three b-sheets; in the same structural arrangement as observed in the CYP109E1 crystal structure, Fig. 7A ). The centrally located heme group is sandwiched between the I and L helices, similarly as in other P450s. The bound heme is covalently attached to the protein by an iron-sulfur bond with Cys351 and is further stabilized by several residues providing van der Waals and hydrophobic interactions, while its propionate side chains interact with the side chains of His91, Arg95, Arg293, and His349. At the distal side of the heme, no clear electron density was observed for a heme-bound water molecule, in contrast to many other P450 crystal structures determined in the substrate-free state. A small blob of electron density is located at approximately 5
A distance from the hemeiron, which may correspond to a glycerol molecule from the cryobuffer, but the quality of the electron density did not allow unambiguous ligand identification. In addition, five PEG 400 molecules and three sulfate ions (SO (Table S2 ). The highest structural similarity is observed with the 'open' crystal structure of CYP109E1 containing four bound corticosterone molecules in the active site pocket (PDB entry 5L91, r.m.s.d. of 1.27 A for 368 Ca atoms). In addition, a significant structural similarity is observed with the structures of Vdh from P. autotrophica, considering . Visual analysis of the CYP109A2, CYP109E1, and Vdh structures shows that they contain similar, wide-open, funnelshaped, and solvent-exposed 'distal' heme pockets. The main difference concerns the BC loop/SRS1 region (loop connecting the B and C helices, residues 71-87 in CYP109A2), whose length, fold, and sequence vary significantly in the structures of the three different enzymes (Figs 2 and 7B) . CYP109A2 contains the shortest BC loop, whereas the longest loop is present in Vdh (Fig. 2) . While the BC loop in CYP109A2 folds toward the active site pocket, the loops in CYP109E1 and especially Vdh are folded more outward ( Figs 7B and 8A) . As a result, the BC loop in CYP109A2 restricts access of substrate to the hemeiron to a larger extent than the BC loops in CYP109E1 and Vdh. The structural differences in the BC loop region further result in a striking difference in the distribution of hydrophobic and polar regions in the active sites of the three P450s (Fig. 8B-D) . In the region closest to the heme, the active site pockets in CYP109A2, CYP109E1, and Vdh display a similar, mainly apolar surface due to the presence of conserved hydrophobic residues, i.e., Leu84, Met85 (SRS1); Leu237, Val240, Ala241 (SRS4); Ile288, Ile291 (SRS5); and Phe389, Val390 (SRS6) in CYP109A2. A bit further away from the heme, however, the surfaces show some significant differences. Residues Arg74, Glu78, Arg79, and Glu81 of the BC loop in CYP109A2 form a highly polar surface restricting one side of the active site pocket (Fig. 8B) . In the active site pocket of CYP109E1, the BC loop also forms a polar surface, but it is much less pronounced as in CYP109A2 (Fig. 8C) , while in Vdh, it is nearly absent (Fig. 8D) . The observed differences in BC loop geometry, in the extent of restricted access to the heme-iron and in the apolar/ polar surface distribution around the active site pocket, will likely influence the substrate-binding modes in the three different enzymes. In the absence of a closed, VD 3 -bound crystal structure of CYP109A2, it remains unknown whether these differences are directly related to the differences in regio-selectivity for VD 3 hydroxylation. Arguably, a significantly more polar BC loop region and a more constricted active site pocket in CYP109A2, in comparison to CYP109E1 or Vdh, allows for lower occurrence of differently stabilized VD 3 -binding modes, therefore resulting in an increased regio-selectivity of substrate hydroxylation in comparison to CYP109E1 or Vdh, as observed experimentally. Indeed, the BC loop, a highly variable and flexible region in P450s, has been previously associated with differences in substrate specificity [37] .
Prediction of vitamin D 3 -binding residues in CYP109A2
Unfortunately, our experiments to crystalize a structure of CYP109A2 in its closed conformation were not successful, despite extensive efforts to obtain a structure of substrate-bound and/or product-bound CYP109A2. The residues known or predicted to bind and stabilize VD 3 in the active sites of CYP109E1 or Vdh were, therefore, compared to their structural equivalents in CYP109A2 (Table 2 ). Based on this comparison, the following 13 residues of CYP109A2 are predicted to interact with VD 3 : Arg74, Leu84, Met85 from SRS1; Leu167, Val168 from SRS2; Arg186, Asn187, Val190 from SRS3; Leu237, Val240, Thr245 from SRS4; Ile291 from SRS5 and Phe389 from SRS6 (Fig. 9) . Of these residues, six are identical to those in CYP109E1 or Vdh, while the other residues are relatively similar. This significant degree of conservation further supports the notion that the overall binding mode of VD 3 leading to 25-hydroxylation is similar in these enzymes. Whether the predicted residues in CYP109A2 indeed have important roles in substrate binding and conversion has to await further analysis by site-directed mutagenesis.
In summary, we have shown that cytochrome P450 monooxygenase CYP109A2 from B. megaterium is able to catalyze hydroxylation of VD 3 to its 25-hydroxylated derivative, with high regio-selectivity. The activity was reconstituted in the whole-cell-based system, allowing to obtain high yields of the desired 25-hydroxylated product and therefore renders the system as most efficient and regio-selective in comparison to other related bacterial P450s previously shown to oxidize VD 3 .
These characteristics highlight the significance of CYP109A2 as a promising, potential industrially applicable biocatalyst. The crystal structure of CYP109A2 allowed for a detailed analysis of the active site geometry and prediction of VD 3 interacting residues. Our study forms the basis to guide future efforts to explore the substrate scope and selectivity of CYP109A2.
Experimental procedures
Materials VD 3 , 25(OH)VD 3 , (2-hydroxypropyl)-b-cyclodextrin and saponin (from quillaja bark) were purchased from SigmaAldrich Chemie GmbH (Steinheim, Germany). IPTG and daminolevulinic acid (d-ALA) were purchased from Carbolution Chemicals GmbH (Saarbruecken, Germany). Bacterial media were purchased from Becton Dickinson (Heidelberg, Germany). All other chemicals were from standard sources and of highest purity available. The E. coli TOP10 strain used for cloning purposes was bought from Invitrogen (San Diego, CA, USA), whereas the E. coli C43 (DE3) strain and pET17b vector used for heterologous expression were purchased from Novagen (Merck Bioscience, Bad Soden, Germany). The pSMF2.1 vector was used for protein expression in B. megaterium MS94 [38] . 
Cloning
The cyp109a2 gene (GenBank GeneID 9117426) was amplified by PCR using genomic DNA of B. megaterium MS941 as template (mutant derived from DSM319 strain) [39, 40] . To allow expression of CYP109A2 carrying a C-terminal His 6 -tag, the cyp109a2 gene was extended with a sequence at the 3 0 -end coding for the desired tag and cloned into the expression vector pET17b with the NdeI/KpnI restriction sites yielding pET17b.CYP109A2. The primer pair used was 5 0 -ATATCATATGAATCCAAAAGCAGT-GAAAAG AGAAAATCG-3 0 and 5 0 -TTAGGTACCTCAATGGTGG TGGTGATGATG-GGCGTTATTAAAAGCAATTTC-3 0 .
The cyp109a2 gene was also cloned into the pSMF2.1 vector using PacI/SpeI restriction sites and including an optimized ribosomal-binding site for B. megaterium, yielding pSMF2. 1 
Heterologous gene expression and purification
The E. coli C43 (DE3) cells serving as expression host were transformed with the pET17b.CYP109A2 construct and cultured overnight in LB medium containing 100 lgÁmL À1 ampicillin, at 37°C and 140 r.p.m. The overnight culture was used to inoculate a 250 mL main culture [Terrific Broth (TB) medium] containing 100 lgÁmL À1 ampicillin.
The main culture was grown at 37°C and 140 r.p.m. until the optical density at 600 nm reached 0.6. Gene expression was induced by addition of 1 mM IPTG and 0.5 mM d-ALA (heme precursor). The culture was further grown at 30°C (120 r.p.m.) for 24 h. The E. coli cells were harvested by centrifugation at 4500 g for 30 min, and cell pellets were stored at -20°C until purification. For biochemical characterization, the protein was purified using a simplified procedure (one-step immobilized metal ion affinity chromatography). For crystallization, a three-step purification protocol was followed, as described previously (ion exchange chromatography, gel filtration, mixed-mode ion exchange chromatography) [18] . Purification of the redox partner protein pairs (BmCPR-Fdx2 and AdR-Adx 4-108 ) was performed according to the previously reported procedures [19, 23] .
Protein quality analysis
Spectroscopic properties of the purified P450 were analyzed using a double-beam spectrophotometer (UV-2101PC; Shimadzu Corporation, Kyoto, Japan). All UV-visible absorbance spectra were recorded from 200 to 700 nm. Concentration of CYP109A2 was estimated based on COdifference spectroscopy (using an extinction coefficient of Fig. 9 . Predicted VD 3 -binding residues in CYP109A2, identified based on structural comparison with CYP109E1 and Vdh ( Table 2) . The residues are shown as sticks and colored according to the corresponding substrate recognition site (SRS1 orange, SRS2 green, SRS3 blue, SRS4 yellow, SRS5 pink, and SRS6 cyan). Residues overlapping in both predictions are labeled in bold. The heme group is shown as red colored sticks. [13] and their structurally equivalent residues in CYP109A2. (B) VD 3 -binding residues in the crystal structure of VD 3 -bound Vdh (PDB id: 3A50) [16] and their structurally equivalent residues in CYP109A2. Residues of CYP109A2 appearing in both panels are highlighted in blue. The residues of CYP109E1 studied previously by site-directed mutagenesis [13, 18] 
Phe389 91 mm À1 Ácm À1 ), according to the method of Omura and
Sato [41] . Protein purity and heterogeneity were analyzed by SDS/PAGE and DLS, respectively. The DLS measurement was performed using a DynaPro NanoStar instrument thermostated at 293 K (Wyatt Instruments, Santa Barbara, CA, USA).
In vitro conversion and kinetic analysis
Enzymatic activity of CYP109A2 was reconstituted in an in vitro system containing 1 lM CYP109A2, 3 lM ferredoxin reductase (BmCPR or AdR), 20 lM ferredoxin (Fdx2 or Adx ), 1 mM MgCl 2 , and a cofactor regenerating system with glucose-6-phosphate (5 mM) and glucose-6-phosphate dehydrogenase (1 U), all in 50 mM potassium phosphate buffer containing 20% glycerol (pH 7.4) and at 250 lL final volume. VD 3 was dissolved in (2-hydroxypropyl)-b-cyclodextrin (2.25%) and added at 200 lM final concentration. The reaction was started by addition of 0.5 mM NADPH at 30°C. After 1 h, the reaction was stopped and extracted twice with 500 lL of ethyl acetate. The organic phases were combined, evaporated to dryness, and prepared for analysis by HPLC. For determination of kinetic parameters of VD 3 conversion by CYP109A2, three independent in vitro reactions were performed (each continuing for 20 min). VD 3 concentrations ranged from 0 to 400 lM. The k cat and K M values were calculated by plotting the product formation rate against increasing substrate concentration. The data were fit to the Michaelis-Menten equation using ORIGIN software from OriginLab Corporation (Northampton, MA, USA).
High-performance liquid chromatography
The HPLC analysis was carried out on a Jasco system (Pu-980 HPLC pump, AS-950 sampler, UV-975 UV-visible detector, LG-980-02 gradient unit; Jasco, Gross-Umstadt, Germany) equipped with a reversed-phase Nucleodur 100-5 C 18 column (125 9 4 mm; Macherey-Nagel, D€ uren, Germany). The column temperature was adjusted to 40°C. The samples were dissolved in 200 lL of acetonitrile. A linear gradient of 60-100% aqueous acetonitrile was applied for 15 min (1 mLÁmin À1 flow rate), followed by 100% acetonitrile for 15 min. The UV detection of the substrate and products was accomplished at 265 nm. Assuming that the absorption properties of the products did not differ from the substrate, the product formation was calculated as the relative peak area (area %) of the HPLC chromatograms, dividing each respective product peak area by the sum of products and substrate areas.
Whole-cell conversion in Bacillus megaterium MS941
The whole-cell conversions were performed in B. megaterium MS941 cells transformed with the pSMF2.1.CYP109A2 construct using the polyethylene glycol-mediated protoplast transformation method [42] . Initial seed culture was prepared in LB medium (10 lgÁmL À1 tetracycline). The main culture (50 mL TB medium, 10 lgÁmL À1 tetracycline) was inoculated with 500 lL of the seed culture (dilution 1 : 100) in 300 mL baffled flasks and incubated under shaking at 37°C (140 r.p.m.). The culture was grown to OD 578 of 0.4, and at that point, the recombinant gene expression was induced with xylose (5 mgÁmL À1 ).
The culture was further grown at 30°C for 24 h (140 r.p.m.). To initialize the whole-cell conversion experiments, after 24 h of protein expression, the substrate [200 lM VD 3 dissolved in 45% (2-hydroxypropyl)-b-cyclodextrin)] and a membrane-solubilizing agent (4% Quillaja Saponin) were added to the cultures. Afterward, the conversions were allowed to proceed at 30°C and 120 r.p.m. for 24 h. Finally, 500 lL samples of the cultures were taken, extracted, and prepared for HPLC analysis.
Product isolation and NMR characterization
In order to obtain sufficient amounts of the reaction product, the whole-cell based cultivation and conversion experiments were scaled up to 400 mL (2 9 200 mL) and performed as described above. The main reaction product (P1) was isolated and purified by reversed-phase HPLC using a preparative column VP Nucleodur 100-5 C 18 (8.0 9 250 mm; Macherey-Nagel). The NMR spectra were recorded in CDCl 3 with a Bruker Avance 500 NMR spectrometer at 298 K (Bruker AXS Advanced X-ray Solutions GmbH, Karlsruhe, Germany For data collection, the crystal was shortly swiped through a cryobuffer droplet [mother liquor supplemented with 30% (v/v) glycerol] and flash-cooled to 100 K in a cold nitrogen gas cryostream. X-ray diffraction data were collected at the ID23-2 beam line of the European Synchrotron Radiation Facility (ESRF) in Grenoble, France. Reflections were indexed and integrated using XDS [43] , while scaling and merging of the data was done with AIM-LESS from the CCP4 software suite [44] . The structure of CYP109A2 was determined by molecular replacement using PHASER from the PHENIX software package [45] , applying the structure of substrate-free CYP109E1 (PDB entry 5L90, [18] ) as a search model. The structure was completed with several cycles of model refinement using PHENIX.REFINE [46] alternated with manual model re-building using COOT [47] . At the final stages of refinement and model building, water molecules were added to the model based on positive difference electron density peaks and strict interaction criteria. The final model was validated with MOLPROBITY [48] . The model coordinates and structure factors are deposited in the PDB with accession code 5OFQ.
Sequence and structure analysis
Protein sequences were compared using the Basic Local Alignment Search Tool (BLAST, NCBI). Substrate recognition sites (SRS) in CYP109A2 were identified by alignment with P450 cam (WP_032492633) and followed a description defined by Gotoh [49] . Pairwise structural alignments were done using PDBEFOLD [50] . Multiple sequence alignment was done with CLUSTAL OMEGA [51] , and the output figure was prepared with ESPRIPT3 [52] . The GenBank accession codes for analyzed sequences are as follows: CYP109A2 from B. megaterium DSM319 (WP_013082916), CYP109E1 from B. megaterium DSM319 (WP_013084555), CYP105A1 from S. griseolus (BAG50411), CYP105A2 from P. autotrophica (BAA05541), Vdh (CYP107BR1) from P. autotrophica (C4B644), CYP107CB2 from B. lehensis G1 (AIC83164).
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